Acucela reports new encouraging data from dry AMD study
Acucela, a biotechnology company, has reported new safety, tolerability and effectiveness data on ACU-4429, an investigational therapy for dry age-related macular degeneration. According to Acucela, study participants tolerated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.